ESR1 and breast carcinoma: Another scenario has occurred in different physiological conditions in women: toremifene is indicated for the treatment of estrogen receptor-positive/or unknown metastatic breast cancer in postmenopausal women but can be extended to premenopausal patients with breast cancer (Gradishar et al., 2022).